INCB 54828

Drug Profile

INCB 54828

Alternative Names: INCB-054828; INCB-54828

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Lymphoid leukaemia; Myeloid leukaemia; Myeloproliferative disorders; Urogenital cancer
  • Phase I/II Cancer; Multiple myeloma
  • Phase I Solid tumours

Most Recent Events

  • 28 Oct 2017 Interim adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I/II trial in multiple myeloma and advanced cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 03 Aug 2017 Incyte Corporation plans a phase I trial for Solid tumours(Late-stage disease) in Japan (NCT03235570)
  • 01 Aug 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Japan (unspecified route) (NCT03235570)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top